Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lenalidomide × Genitourinary × Clear all

Phase

Phase 2 7 Phase 1/2 5 Phase 1 5 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 78 Lymphoid 38 Other hematologic neoplasm 5 Myeloid 2 Dermatologic 2 Sarcoma 1 Genitourinary 1 Classical hematology 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 65 Radiotherapy 59 Prednisone 54 Goserelin 40 Gemcitabine 40 Cisplatin 40 Leuprolide 38 enzalutamide 36 bicalutamide 35 Androgen Antagonists 30 pembrolizumab 27 Mitomycin 26 Carboplatin 25 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 24 Abiraterone Acetate 23 Magnetic Resonance Spectroscopy 22 Sunitinib 19 Nivolumab 19 Flutamide 19 apalutamide 18 Triptorelin Pamoate 17 Radiation 17 Doxorubicin 16 cabozantinib 13 atezolizumab 13 abiraterone 13 Zoledronic Acid 13 Radiosurgery 13 Paclitaxel 13 darolutamide 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00988208 2018-04-04

Mainsail

Celgene

Phase 3 Completed

1,059 enrolled 27 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡